SCHEMBL4664847

SCHEMBL4664847

COc1ccc(CC(=O)O)c(C)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.65
AKR1C2 P52895 2/20 0.56
PTGS1 P23219 1/20 0.56
AKR1C3 P42330 1/20 0.56
HTT P42858 1/20 0.55
KDM4E B2RXH2 3/20 0.55
POLB P06746 2/20 0.53
LCK P06239 1/20 0.52
MEN1 O00255 1/20 0.49
KMT2A Q03164 1/20 0.49
RXRA P19793 2/20 0.49
RXRB P28702 2/20 0.49
RXRG P48443 1/20 0.48
ABL1 P00519 1/20 0.47
MAPT P10636 1/20 0.47
RECQL P46063 1/20 0.47
RIN1 Q13671 1/20 0.47
CTDSP1 Q9GZU7 1/20 0.47
PPARD Q03181 1/20 0.47
MMP2 P08253 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1922374 0.86 CYP3A4 (0.49) HSD17B10AKR1C2PTGS1AKR1C3HTT
SCHEMBL3918324 0.84 ALDH1A1 (0.54) HSD17B10AKR1C2PTGS1AKR1C3HTT
SCHEMBL27561318 0.84 RXRA (0.48) HSD17B10AKR1C2PTGS1AKR1C3HTT
SCHEMBL3296862 0.84 POLB (0.73) HSD17B10AKR1C2PTGS1AKR1C3HTT
SCHEMBL30335932 0.84 POLB (0.73) HSD17B10AKR1C2PTGS1AKR1C3HTT
SCHEMBL25648716 0.83 POLB (0.71) HSD17B10HTTKDM4EPOLBMEN1
SCHEMBL30831943 0.82 HSD17B10 (0.75) HSD17B10AKR1C2PTGS1AKR1C3KDM4E
SCHEMBL15935612 0.82 HSD17B10 (0.70) HSD17B10AKR1C2PTGS1AKR1C3KDM4E
SCHEMBL1097902 0.82 HSD17B10 (0.75) HSD17B10AKR1C2PTGS1AKR1C3KDM4E
SCHEMBL983847 0.82 HSD17B10 (0.65) HSD17B10AKR1C2PTGS1AKR1C3HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118164833-B Synthesis method and application of aromatic butanone compound 云南大学 2024-08-09 CN claimed
CN-118164833-A Synthesis method and application of aromatic butanone compound 云南大学 2024-06-11 CN claimed
CN-118164833-B Synthesis method and application of aromatic butanone compound 云南大学 2024-08-09 CN disclosed
CN-118164833-A Synthesis method and application of aromatic butanone compound 云南大学 2024-06-11 CN disclosed
WO-2021072156-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2019057946-A1 MULTI-CYCLIC AROMATIC COMPOUNDS AS FACTOR D INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2019-03-28 WO disclosed
US-9700543-B2 GLP-1 receptor stabilizers and modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-07-11 US disclosed
EP-2713722-B1 NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS RECEPTOS LLC (US) 2017-03-15 EP disclosed
US-20160310471-A1 NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS RECEPTOS LLC 2016-10-27 US disclosed
US-9278910-B2 GLP-1 receptor stabilizers and modulators RECEPTOS, INC. (US) 2016-03-08 US disclosed
US-20140336185-A1 NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS RECEPTOS LLC 2014-11-13 US disclosed
WO-2012166951-A9 NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS RECEPTOS, INC. (US) 2013-02-21 WO disclosed
WO-2012166951-A1 NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS RECEPTOS, INC. (US) 2012-12-06 WO disclosed
US-20080132562-A1 TETRONIC AND TETRAMIC ACIDS GODEL THIERRY 2008-06-05 US disclosed
EP-1689729-A1 TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE F. Hoffmann-La Roche AG (CH) 2006-08-16 EP disclosed
WO-2005058857-A1 TETRONIC AND TETRAMIC ACIDS AS INHIBITORS OF BETA-SECREASE F. HOFFMANN-LA ROCHE AG (CH) 2005-06-30 WO disclosed
US-20050119329-A1 Tetronic and tetramic acids HOFFMANN-LA ROCHE INC. 2005-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336185-A1 NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS GLP1R, GIPR, GHSR HSD17B10 4277/4885AKR1C2 3682/4885PTGS1 1756/4885
US-20080132562-A1 TETRONIC AND TETRAMIC ACIDS BACE1, PSEN1, BACE2 HSD17B10 1577/4885AKR1C2 2018/4885PTGS1 2900/4885
US-20050119329-A1 Tetronic and tetramic acids BACE1, PSEN1, BACE2 HSD17B10 1577/4885AKR1C2 2018/4885PTGS1 2900/4885
US-20160310471-A1 NOVEL GLP-1 RECEPTOR STABILIZERS AND MODULATORS GLP1R, GIPR, GHSR HSD17B10 4277/4885AKR1C2 3682/4885PTGS1 1756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.